Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

542
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
542
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

10.4K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
10.4K
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

575
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
575
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

807
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
807
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Age-related differences in the intake of heart failure therapy among participants from the MyoVasc study.

European geriatric medicine·2026
Same author

Global and regional DNA methylation patterns in heart failure: a case-control analysis.

EBioMedicine·2026
Same author

Hearing loss and executive functions - results from a population-based cohort study.

PloS one·2026
Same author

Chronotropic response in heart failure: clinical, structural, and metabolic predictors and long-term mortality.

European journal of heart failure·2026
Same author

Blood DNA Methylation Patterns Across Carotid, Coronary, and Peripheral Atherosclerosis: A Comparative Analysis in 2 Prospective Cohorts.

Journal of the American College of Cardiology·2026
Same author

Longitudinal evaluation of the psychometric stability of the somatic symptom scale-8 (SSS-8) in a large German general population sample.

Scientific reports·2026

Related Experiment Video

Updated: Mar 13, 2026

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2
10:31

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2

Published on: September 26, 2025

596

Pathophysiological insights into the antiphospholipid syndrome.

Karl J Lackner1, Davit Manukyan, Nadine Müller-Calleja

  • 1Karl J. Lackner, MD Institute of Clinical Chemistry and Laboratory Medicine University Medical Centre Mainz 55131 Mainz Germany, Tel: +49 6131 177190 Fax: +49 6131 176627

Hamostaseologie
|October 28, 2016
PubMed
Summary

Antiphospholipid antibodies (aPL) cause antiphospholipid syndrome (APS) through complex mechanisms. Novel research challenges the traditional view of cofactor-independent aPL being non-pathogenic, suggesting a broader pathogenic role.

Keywords:
antiphospholipid antibodiesantiphospholipid syndromethrombosisß2-glycoprotein I

More Related Videos

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

1.3K
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

1.2K

Related Experiment Videos

Last Updated: Mar 13, 2026

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2
10:31

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2

Published on: September 26, 2025

596
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

1.3K
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

1.2K

Area of Science:

  • Immunology
  • Rheumatology
  • Hematology

Background:

  • Antiphospholipid syndrome (APS) involves thrombosis and pregnancy complications linked to antiphospholipid antibodies (aPL).
  • The precise pathogenic mechanisms of various aPL types remain debated, impacting diagnosis and treatment strategies.

Purpose of the Study:

  • To review current data on the pathogenetic roles of different antiphospholipid antibody (aPL) types in antiphospholipid syndrome (APS).
  • To discuss the implications of recent findings for APS diagnosis and future research directions.

Main Methods:

  • Literature review of studies investigating antiphospholipid antibodies (aPL) and their association with antiphospholipid syndrome (APS).
  • Analysis of data concerning cofactor-dependent and cofactor-independent aPL, including those binding directly to cofactor proteins.

Main Results:

  • Antiphospholipid antibodies (aPL) are categorized into cofactor-independent, cofactor-dependent (e.g., anti-ß2GPI), and those binding directly to cofactor proteins.
  • Emerging evidence suggests cofactor-independent aPL may possess pathogenic roles, challenging the long-held belief of their non-pathogenicity.

Conclusions:

  • The heterogeneity of antiphospholipid antibodies (aPL) contributes to the complex pathogenesis of antiphospholipid syndrome (APS).
  • Re-evaluation of the pathogenic potential of all aPL types is crucial for refining APS diagnostic criteria and guiding future therapeutic research.